JP2017527623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527623A5 JP2017527623A5 JP2017533154A JP2017533154A JP2017527623A5 JP 2017527623 A5 JP2017527623 A5 JP 2017527623A5 JP 2017533154 A JP2017533154 A JP 2017533154A JP 2017533154 A JP2017533154 A JP 2017533154A JP 2017527623 A5 JP2017527623 A5 JP 2017527623A5
- Authority
- JP
- Japan
- Prior art keywords
- gel composition
- composition according
- pharmaceutical gel
- pharmaceutical
- levodopa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008252 pharmaceutical gel Substances 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 25
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 20
- 229960003638 dopamine Drugs 0.000 claims 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 9
- 229960004502 levodopa Drugs 0.000 claims 9
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 8
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 8
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 229960004205 carbidopa Drugs 0.000 claims 4
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 4
- 229960003337 entacapone Drugs 0.000 claims 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical group CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000008365 aqueous carrier Substances 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019210309A JP6889231B2 (ja) | 2014-09-04 | 2019-11-21 | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1451034-1 | 2014-09-04 | ||
| SE1550344 | 2015-03-24 | ||
| SE1550344-4 | 2015-03-24 | ||
| PCT/SE2015/050939 WO2016036308A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019210309A Division JP6889231B2 (ja) | 2014-09-04 | 2019-11-21 | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527623A JP2017527623A (ja) | 2017-09-21 |
| JP2017527623A5 true JP2017527623A5 (enExample) | 2018-10-11 |
| JP6622310B2 JP6622310B2 (ja) | 2019-12-18 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533154A Active JP6622310B2 (ja) | 2014-09-04 | 2015-09-04 | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
| JP2019210309A Active JP6889231B2 (ja) | 2014-09-04 | 2019-11-21 | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019210309A Active JP6889231B2 (ja) | 2014-09-04 | 2019-11-21 | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10071069B2 (enExample) |
| EP (3) | EP3782617B1 (enExample) |
| JP (2) | JP6622310B2 (enExample) |
| CN (1) | CN107072973A (enExample) |
| AU (3) | AU2015312430B2 (enExample) |
| CA (2) | CA3175785A1 (enExample) |
| DK (2) | DK3782617T3 (enExample) |
| ES (2) | ES2973289T3 (enExample) |
| FI (1) | FI3782617T3 (enExample) |
| HR (2) | HRP20240314T1 (enExample) |
| HU (2) | HUE052857T2 (enExample) |
| PL (2) | PL3782617T3 (enExample) |
| PT (2) | PT3188725T (enExample) |
| RS (1) | RS65337B1 (enExample) |
| SI (2) | SI3188725T1 (enExample) |
| WO (1) | WO2016036308A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2973289T3 (es) | 2014-09-04 | 2024-06-19 | Lobsor Pharmaceuticals Ab | Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona |
| RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| SG11201808713YA (en) * | 2016-04-11 | 2018-11-29 | Univ Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| US20180021280A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and Carbidopa Intestinal Gel and Methods of Use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| WO2018146194A1 (en) | 2017-02-13 | 2018-08-16 | Bayer Animal Health Gmbh | Liquid composition containing pradofloxacin |
| CN111902136A (zh) * | 2017-12-28 | 2020-11-06 | 瑞璞鑫(苏州)生物科技有限公司 | 用于预防和/或治疗肥胖症和相关代谢性疾病的托卡朋 |
| CN118121710A (zh) * | 2018-03-23 | 2024-06-04 | 劳波索尔制药有限公司 | 用于治疗神经退行性疾病的药物组合物的连续施用 |
| EP3593819A1 (en) | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| MX368750B (es) * | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| TWI831896B (zh) * | 2018-12-18 | 2024-02-11 | 美商美國禮來大藥廠 | 用於治療多巴胺性cns病症之ly3154207劑量療法 |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| JP2023517690A (ja) * | 2020-03-13 | 2023-04-26 | ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ | 微粉化オピカポン |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| WO2022158991A1 (en) * | 2021-01-20 | 2022-07-28 | Bial-Portela & Ca., S.A. | Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| HK1041441A1 (zh) * | 1998-11-10 | 2002-07-12 | Teva Pharmaceutical Industries, Ltd. | 包含l-多巴乙酯的可分散组合物 |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| ES2360759T3 (es) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| MXPA06002344A (es) | 2003-08-29 | 2006-05-19 | Transform Pharmaceuticals Inc | Composiciones farmaceuticas y metodo para usar levodopa y carbidopa. |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| RU2484815C2 (ru) | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| US8741342B2 (en) | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| EP2252284B1 (en) | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| US20130253056A1 (en) * | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| ES2627655T3 (es) * | 2009-05-19 | 2017-07-31 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de DOPA descarboxilasa |
| JP5902705B2 (ja) | 2010-11-15 | 2016-04-13 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| JP6472391B2 (ja) | 2013-03-13 | 2019-02-20 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | パーキンソン病の治療方法 |
| ES2973289T3 (es) | 2014-09-04 | 2024-06-19 | Lobsor Pharmaceuticals Ab | Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en not_active Ceased
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 HR HRP20210025TT patent/HRP20210025T1/hr unknown
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US12156858B2/en active Active
-
2024
- 2024-10-21 US US18/921,791 patent/US20250041257A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527623A5 (enExample) | ||
| FI3782617T3 (fi) | Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia | |
| MX384021B (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| JP2016535777A5 (enExample) | ||
| JP2013525501A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| JP2016534153A5 (enExample) | ||
| MX2020007227A (es) | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. | |
| JP2017535616A5 (enExample) | ||
| IN2014MN01706A (enExample) | ||
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| JP2017507973A5 (enExample) | ||
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| CR20140053A (es) | Formulaciones de ácido desoxicólico y sales del mismo | |
| BR112017026202A2 (pt) | composição modificadora da reologia seca, método de preparação da composição modificadora da reologia seca, formulação de produto e método de preparação de formulação | |
| JP2011251985A5 (enExample) | ||
| NZ752214A (en) | Arsenic compositions | |
| MY204440A (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
| PH12022552257A1 (en) | Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3- methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5- (trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and sodium ions | |
| JP2016526379A5 (enExample) | ||
| PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
| JP2015120758A5 (enExample) | ||
| RU2018101220A (ru) | Продукт на основе хелата бис-глицината железа и альгиновой кислоты и/или ее водорастворимых солей, его составы и его фармацевтические применения | |
| CN105707073A (zh) | 一种缓释型光谱抗菌剂及其制备方法 | |
| JP2017508004A5 (enExample) |